Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

16.18USD
24 Feb 2017
Change (% chg)

$-0.40 (-2.41%)
Prev Close
$16.58
Open
$16.50
Day's High
$16.53
Day's Low
$16.11
Volume
1,915,235
Avg. Vol
2,856,985
52-wk High
$86.50
52-wk Low
$13.00

VRX.N

Chart for VRX.N

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.13
Market Cap(Mil.): $5,525.78
Shares Outstanding(Mil.): 341.19
Dividend: --
Yield (%): --

Financials

  VRX.N Industry Sector
P/E (TTM): -- 28.84 29.63
EPS (TTM): -6.48 -- --
ROI: -5.29 13.44 12.96
ROE: -42.94 14.34 14.11

Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc, causing billions of dollars of losses.

Feb 24 2017

Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

NEW YORK A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc , causing billions of dollars of losses.

Feb 24 2017

Sequoia Fund wins dismissal of lawsuit over huge Valeant stake

NEW YORK, Feb 24 A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc , causing billions of dollars of losses.

Feb 24 2017

Former Valeant and Philidor execs plead not guilty in fraud scheme

A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.

Feb 23 2017

Former Valeant and Philidor executives plead not guilty in fraud scheme

NEW YORK A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.

Feb 23 2017

Former Valeant and Philidor execs plead not guilty in fraud scheme

NEW YORK, Feb 23 A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.

Feb 23 2017

BRIEF-Valeant Pharmaceuticals CEO: sales growth, cutting debt top priorities

Feb 23 Valeant Pharmaceuticals International Inc CEO Joe Papa, speaking at RBC investor conference in New York:

Feb 23 2017

BRIEF-Valeant unit Obagi Medical Products collaborates with Nextcell Medical

* Obagi Medical Products-collaboration with Nextcell Medical Co to claim exclusive distribution of Suzan Obagi's line of skin care products throughout U.S. Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing

* Eyegate Pharmaceuticals Inc - under license agreement, Valeant will pay company an upfront payment of $4.0 million - SEC filing

Feb 21 2017

BRIEF-Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product

* Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product in post-operative pain and inflammation in ocular surgery patients

Feb 21 2017

More From Around the Web

Earnings vs. Estimates